Aquestive Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Aquestive Therapeutics, Inc. (AQST) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 37.07 million shares for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-03.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-08-03
- Aquestive Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 37.07M shares, a 10.35% increase year-over-year.
- Aquestive Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 33.83M shares, a 27.90% increase year-over-year.
- Aquestive Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 33.62M shares, a 34.31% increase year-over-year.
- Aquestive Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 33.59M shares, a 34.46% increase year-over-year.
- Aquestive Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 33.65M shares, a 32.71% increase from fiscal 2019.
- Aquestive Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 25.36M shares, a 22.34% increase from fiscal 2018.
- Aquestive Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 20.73M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-06-30 | 37.07M shares 10-Q · filed 2021-08-03 | 36.32M shares 10-Q · filed 2021-08-03 | ||
| 2020-12-31 | 33.83M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | 33.72M shares derived: average of 2 quarters · filed 2021-03-09 | 33.68M shares derived: average of 3 quarters · filed 2021-08-03 | 33.65M shares 10-K · filed 2021-03-09 |
| 2020-09-30 | 33.62M shares 10-Q · filed 2020-11-04 | 33.60M shares derived: average of 2 quarters · filed 2021-08-03 | 33.59M shares 10-Q · filed 2020-11-04 | 31.81M shares derived: average of 4 quarters · filed 2021-08-03 |
| 2020-06-30 | 33.59M shares 10-Q · filed 2021-08-03 | 33.58M shares 10-Q · filed 2021-08-03 | 31.20M shares derived: average of 3 quarters · filed 2021-08-03 | 29.66M shares derived: average of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | 33.57M shares 10-Q · filed 2020-05-05 | 30.01M shares derived: average of 2 quarters · filed 2021-03-09 | 28.35M shares derived: average of 3 quarters · filed 2021-03-09 | 27.51M shares derived: average of 4 quarters · filed 2021-03-09 |
| 2019-12-31 | 26.45M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | 25.74M shares derived: average of 2 quarters · filed 2021-03-09 | 25.49M shares derived: average of 3 quarters · filed 2021-03-09 | 25.36M shares 10-K · filed 2021-03-09 |
| 2019-09-30 | 25.03M shares 10-Q · filed 2020-11-04 | 25.01M shares derived: average of 2 quarters · filed 2020-11-04 | 24.99M shares 10-Q · filed 2020-11-04 | 24.97M shares derived: average of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | 24.98M shares 10-Q · filed 2020-08-04 | 24.97M shares 10-Q · filed 2020-08-04 | 24.95M shares derived: average of 3 quarters · filed 2020-08-04 | 24.62M shares derived: average of 4 quarters · filed 2020-08-04 |
| 2019-03-31 | 24.96M shares 10-Q · filed 2020-05-05 | 24.93M shares derived: average of 2 quarters · filed 2020-05-05 | 24.50M shares derived: average of 3 quarters · filed 2020-05-05 | 23.17M shares derived: average of 4 quarters · filed 2020-05-05 |
| 2018-12-31 | 24.90M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | 24.27M shares derived: average of 2 quarters · filed 2020-03-11 | 22.58M shares derived: average of 3 quarters · filed 2020-03-11 | 20.73M shares 10-K · filed 2020-03-11 |
| 2018-09-30 | 23.65M shares 10-Q · filed 2019-11-05 | 21.42M shares derived: average of 2 quarters · filed 2019-11-05 | 19.34M shares 10-Q · filed 2019-11-05 | |
| 2018-06-30 | 19.19M shares 10-Q · filed 2019-08-06 | 17.14M shares 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | 15.08M shares 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |